Chronic treatment of APP/PS transgenic AD model mice with NTI alleviated Aβ pathology and improved cognitive deficits in spatial reference memory by reducing activities of endogenous BACE1 and γ-secretase without any changes in APP expression levels or Aβ clearance (Teng et al., 2010). Here, BACE1 is linked to Alzheimer disease.